Interaction Checker

Three targeted therapies have been added to the interaction checker.

Friday 25 May 2018

Avelumab, niraparib and tivozanib are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications.

  • Avelumab (Bavencio®) is a monoclonal antibody and is indicated for the treatment of Merkel cell carcinoma.
  • Niraparib (Zejula®) is a PARP inhibitor and is indicated for the treatment of epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
  • Tivozanib (Fotivda®) is a VEGFR1/2/3 inhibitor and is indicated for the treatment of renal cell carcinoma.
ENDORSED BY
Bopa